Sanofi’s flirtation with services: A sure sign of desperation
David Williams says comments by Sanofi-Aventis' CEO only highlight the rough road ahead for big pharma. Drug companies are likely "contemplating how to surround on-patent and off-patent drugs with services that make them more valuable to the buyers." But Williams wonders if that strategy is even possible.